Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Trial Details

NCT ID

NCT06140966

Phase

PHASE2

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

• Daratumumab
• Carfilzomib
• Lenalidomide
• Dexamethasone
• Cisplatin
• epirubicin

Locations (sample)

• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• Patients must have newly diagnosed ultra high-risk disease, as defined by one of the following:1)"Double hit"Multiple Myeloma (≥2 adverse markers: …
• Patients must be either untreated or have not received systemic MM therapy. Prior bisphosphonates and localized radiation are allowed.
• Aged 18 years to 70 years.
• Fit for intensive chemotherapy and autologous stem cell transplant (at clinician's discretion).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.